The publisher explores Eisai’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (5 November 2020)
Model updates (31 January 2020)
Model updates (31 October 2019)
Model updates (14 August 2019)
Snapshot
- Overview - Eisai’s growth will continue to be driven by Lenvima in the mid-term, with pipeline neurology products adding significant revenues thereafter.
- Key themes - [1] Eisai’s growth is due to approvals in additional indications for Lenvima [2] Eisai’s longer-listed products, such as Aricept, have shown to be able to retain more market share than previously expected [3] Eisai will look to gain approvals for key Alzheimer's disease pipeline products aducanumab and BAN2401 to provide long-term growth.
Model updates (5 November 2020)
- Humira forecast adjusted higher
- Halaven forecast adjusted higher
- Lenvima forecast adjusted higher due to long-term growth in multiple tumor types
- BAN2401 forecast added.
Model updates (31 January 2020)
- Lenvima RoW forecast adjusted higher due to growth in China’s HCC market
- Halaven RoW forecast adjusted higher due to launch in China for breast cancer.
Model updates (31 October 2019)
- Aducanumab forecast added.
Model updates (14 August 2019)
- Lenvima forecast adjusted higher due to revenue from additional indications
- Aricept forecast adjusted higher due to company guidance
- Lunesta forecast adjusted higher due to company guidance
- Aciphex Japan forecast adjusted lower due to generics, and RoW forecast adjusted higher due to China company guidance
- Belviq forecast adjusted lower due to RoW company guidance.
Table of Contents
Company Background
Company Forecast
Company Profile
Clinical Trial Overview
